ArticleHemaSphere2026

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma.

Ondrej Venglar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.